Article

Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis.

Third Department of Internal Medicine, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Modern Rheumatology (Impact Factor: 2.21). 02/2008; 18(3):315-8. DOI: 10.1007/s10165-008-0053-0
Source: PubMed

ABSTRACT A 63-year-old woman with active rheumatoid arthritis (RA) had been treated with methotrexate and prednisolone. She developed cervical lymph node swelling 30 months after the initiation of infliximab therapy. A computed tomography revealed cervical and mediastinal lymph node swelling and multiple nodules (up to 13 mm in diameter) in the lungs. A lymph node biopsy showed infiltration of numerous Hodgkin-like and Reed-Sternberg-like cells. Immunohistological studies showed that these cells were positive for CD15, CD30, and Epstein-Barr virus (EBV) latent membrane protein. In site hybridization revealed the presence of EBV RNA in the nuclei of these cells. EBV DNA was detected in the biopsy specimen by southern blot analysis. She was diagnosed as having EBV-associated lymphoproliferative disorder (LPD). Immunodeficiency-associated LPD related with infliximab therapy was considered. Cessation of infliximab therapy only led to dramatic regression of LPD. This case illustrates that EBV-associated LPDs can occur as part of infliximab adverse effects in patients with RA.

0 Bookmarks
 · 
67 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectifs Le risque de lymphome est accru dans la polyarthrite rhumatoïde (PR), contrairement à la spondylarthrite ankylosante (SA). Le rôle de l’EBV dans la survenue des lymphomes au cours de la PR reste discuté. Méthode Nous avons étudié de manière prospective l’évolution de la charge virale EBV (CvEBV) de patients atteints de PR ou de SA traités par anti-TNFα, ainsi que le lien avec l’activité de la maladie. Résultats Les 46 patients atteints de PR (femmes : 82,6 %), étaient âgées de 52,7 ± 11,3 ans. La CvEBV a été contrôlée à 9,72 ± 5,7 mois. Elle est devenue positive chez cinq patients et a augmenté chez un autre (quatre sous etanercept, un sous adalimumab, un sous infliximab). Elle est devenue négative chez six patients (cinq patients sous adalimumab, un sous étanercept). Le DAS 28 est passé de 4,78 ± 1,1 à l’inclusion à 2,94 ± 1,24. Les 27 patients atteints de SA (hommes : 81,5 %) étaient âgés de 45,1 ± 12,7 ans. La CvEBV a été contrôlée à 12,9 ± 10,6 mois. Elle est devenue positive chez deux patients (7,4 %) (un sous infliximab, un sous adalimumab), indétectable chez un patient sous adalimumab. Sous traitement, le BASDAI est passé de 55,1 ± 16,2 à 17,8 ± 18,6. Une CvEBV positive est plus fréquente dans la PR que dans la SA (p = 0,039). Aucun cas de lymphome n’a été recensé. Conclusion L’introduction d’un traitement anti-TNFα n’influence pas la CvEBV de patients traités pour une PR ou une SA.
    Revue du Rhumatisme 10/2010; 77(5):463-466.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 73-year-old female, diagnosed with rheumatoid arthritis (RA), complicated with severe levels of joint destruction, started etanercept (ETN) because of high persistent RA disease activity. Although her articular symptoms dramatically improved, she developed marked pancytopenia after the introduction of ETN. Bone marrow aspirate specimen revealed hypocellular marrow in three hematopoietic series without atypical findings, which was compatible with aplastic anemia (AA). This is a rare case of severe pancytopenia due to AA presumably induced by ETN.
    Central European Journal of Medicine 7(5). · 0.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoproliferative disorders (LPDs) may involve intrathoracic organs in patients with autoimmune disease, but little is known about the radiologic manifestations of autoimmune disease-associated LPDs (ALPDs) of the lungs. The purpose of our work was to identify the radiologic characteristics of pulmonary involvement in ALPDs. A comprehensive search for PubMed database was conducted with the combination of MeSH words. All articles which had original images or description on radiologic findings were included in this analysis. Also, CT images of eight patients with biopsy-proven lymphoproliferative disorder observed from our institution were added. Overall, 44 cases of ALPD were identified, and consisted of 24 cases of bronchus-associated lymphoid tissue lymphoma (BALToma), eight cases of non-Hodgkin's lymphoma (NHL), six cases of lymphoid interstitial pneumonia (LIP), two cases of nodular lymphoid hyperplasia, two cases of unclassified lymphoproliferative disorder, and one case each of lymphomatoid granulomatosis and hyperblastic BALT. Multiple nodules (n = 14, 32 %) and single mass (n = 8, 18 %) were the predominant radiologic manifestations. The imaging findings conformed to previously described findings of BALToma, NHL, or LIP. Data suggest that BALToma, NHL, and LIP are the predominant ALPDs of the lung, and ALPD generally shared common radiologic features with sporadic LPDs. Familiarity with ALPDs and their imaging findings may enable radiologists or clinicians to include the disease as a potential differential diagnosis and thus, to prompt early biopsy followed by appropriate treatment.
    Clinical Rheumatology 06/2013; · 1.77 Impact Factor